Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study

OBJECTIVES: Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Thorne, Carter, Karpouzas, George, Sheng, Shihong, Xu, Weichun, Rao, Ravi, Fei, Kaiyin, Hsu, Benjamin, Tak, Paul P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705845/
https://www.ncbi.nlm.nih.gov/pubmed/28855173
http://dx.doi.org/10.1136/annrheumdis-2017-211328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705845/
https://www.ncbi.nlm.nih.gov/pubmed/28855173
http://dx.doi.org/10.1136/annrheumdis-2017-211328

Ejemplares similares